Hospital
Prime Healthcare Paradise Valley LLC
Prime Healthcare Paradise Valley LLC was paid $12.56M by Medicaid between Jan 2018 and Dec 2024, across 183 billing codes. Its largest line is 0450, Emergency room services — 12% of everything it billed.
33Billing provider infoPRIME HEALTHCARE PARADISE VALLEY LLC
NATIONAL CITY, CA 91950
NATIONAL CITY, CA 91950
33aNPI1356410351assigned 11/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.56M
24GClaims486,701
24DCodes billed183
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#160 of 410
Median peer was paid$6.90M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 103,854 | $2.91M | |
| 2019 | 81,356 | $2.33M | |
| 2020 | 53,538 | $1.39M | |
| 2021 | 64,171 | $1.57M | |
| 2022 | 68,779 | $1.66M | |
| 2023 | 62,982 | $1.54M | |
| 2024incomplete | 52,021 | $1.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 12% | 28,388 | 25,376 | $1.46M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10.0% | 22,100 | 20,096 | $1.25M |
| 0915 | 8.3% | 1,511 | 224 | $1.04M | |
| 99499 | 5.6% | 7,946 | 6,626 | $705K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.9% | 8,024 | 7,492 | $487K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.5% | 7,086 | 5,880 | $442K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 3,703 | 3,555 | $392K |
| Z7502 | 2.9% | 9,954 | 9,713 | $368K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.8% | 5,948 | 5,520 | $356K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 3,450 | 3,212 | $351K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 1,480 | 1,435 | $339K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 13,125 | 11,790 | $303K |
171 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.2% | 8,306 | $278K |
| 80053 | Comprehensive metabolic panel | 2.2% | 27,728 | $272K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 5,532 | $237K |
| 99284 | Emergency room visit (serious) | 1.8% | 3,343 | $225K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 32,509 | $215K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.7% | 12,929 | $207K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 7,060 | $198K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,708 | $195K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 2,048 | $162K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 5,566 | $143K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 1,549 | $126K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,505 | $114K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 735 | $109K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 880 | $106K |
| 0914 | <1% | 161 | $88K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,744 | $88K |
| 83880 | <1% | 4,539 | $87K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,149 | $87K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,342 | $81K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,605 | $79K |
| 84484 | <1% | 9,748 | $78K | |
| 31623 | <1% | 901 | $76K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,432 | $76K |
| 0762 | <1% | 93 | $74K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,079 | $63K |
| Z7610 | <1% | 5,956 | $60K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,275 | $58K |
| 83690 | <1% | 8,678 | $56K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,656 | $55K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,127 | $52K |
| 0250 | <1% | 7,351 | $49K | |
| 90715 | <1% | 1,161 | $49K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,383 | $44K |
| 0760 | <1% | 334 | $41K | |
| 84702 | <1% | 4,928 | $39K | |
| 99406 | <1% | 2,967 | $35K | |
| 0270 | <1% | 4,177 | $35K | |
| 81001 | <1% | 9,542 | $31K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,700 | $30K |
| 88108 | <1% | 645 | $30K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,571 | $30K |
| 87800 | <1% | 1,636 | $30K | |
| 99199 | Unlisted special service, procedure or report | <1% | 542 | $30K |
| 0710 | <1% | 809 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,651 | $26K |
| 82962 | <1% | 9,627 | $26K | |
| 31624 | <1% | 872 | $25K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,761 | $25K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,551 | $23K |
| 73630 | <1% | 879 | $22K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 177 | $22K |
| 0510 | <1% | 1,333 | $22K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 239 | $21K |
| 73562 | <1% | 894 | $21K | |
| 88312 | <1% | 688 | $20K | |
| 73610 | <1% | 701 | $20K | |
| 87070 | <1% | 1,735 | $20K | |
| 82550 | <1% | 3,483 | $19K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 873 | $18K |
| 83605 | <1% | 1,823 | $17K | |
| 76801 | <1% | 235 | $17K | |
| J3490 | Unclassified drugs | <1% | 39,346 | $15K |
| 87430 | <1% | 1,463 | $15K | |
| 73130 | <1% | 526 | $15K | |
| 87186 | <1% | 2,116 | $15K | |
| 87015 | <1% | 1,726 | $14K | |
| 87101 | <1% | 1,312 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,545 | $13K |
| 87040 | <1% | 1,262 | $12K | |
| 87206 | <1% | 1,556 | $12K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 169 | $12K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,045 | $12K |
| 73030 | <1% | 481 | $12K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 509 | $11K |
| 84703 | <1% | 2,986 | $11K | |
| 85730 | <1% | 2,481 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 237 | $11K |
| 87220 | <1% | 1,751 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 316 | $10K |
| 85610 | <1% | 3,205 | $9K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 106 | $8K |
| 81003 | <1% | 3,530 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,494 | $8K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 106 | $8K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,178 | $7K |
| 29125 | <1% | 195 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,182 | $7K |
| 81025 | <1% | 1,342 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 831 | $7K |
| 87077 | <1% | 1,159 | $7K | |
| 88184 | <1% | 145 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 89 | $7K |
| 87205 | <1% | 946 | $6K | |
| 72100 | <1% | 211 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,746 | $6K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 514 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,092 | $6K |
| 94644 | <1% | 239 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,338 | $5K |
| 83735 | <1% | 1,370 | $5K | |
| 93971 | <1% | 41 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 92 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 713 | $4K |
| 70486 | <1% | 38 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 185 | $4K |
| 85379 | <1% | 423 | $4K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 150 | $3K |
| 88185 | <1% | 144 | $3K | |
| 82553 | <1% | 318 | $3K | |
| 97750 | <1% | 53 | $3K | |
| 73110 | <1% | 89 | $3K | |
| 97116 | <1% | 215 | $3K | |
| 80076 | <1% | 359 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 99 | $2K |
| 80164 | <1% | 222 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 371 | $2K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 93 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 77 | $2K |
| 12001 | <1% | 41 | $2K | |
| 59025 | Fetal non-stress test | <1% | 86 | $2K |
| 86901 | <1% | 562 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 133 | $1K |
| 29505 | <1% | 27 | $1K | |
| 80061 | Lipid panel | <1% | 1,032 | $1K |
| 76770 | <1% | 15 | $1K | |
| 12002 | <1% | 15 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 353 | $1K |
| 51701 | <1% | 13 | $1K | |
| 84439 | <1% | 510 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 173 | $970.92 |
| 87420 | <1% | 86 | $944.24 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $933.74 |
| 74022 | <1% | 27 | $880.56 | |
| 88112 | <1% | 68 | $876.72 | |
| 81002 | <1% | 402 | $872.77 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 862 | $785.49 |
| 72040 | <1% | 28 | $703.73 | |
| 10060 | <1% | 15 | $671.81 | |
| 0324 | <1% | 13 | $671.56 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 17 | $645.71 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 58 | $606.95 |
| 82948 | <1% | 231 | $599.20 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 57 | $597.79 |
| 90840 | <1% | 21 | $541.51 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 54 | $454.26 |
| 73080 | <1% | 12 | $390.57 | |
| 82150 | <1% | 50 | $384.92 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 39 | $271.15 |
| 94645 | <1% | 12 | $205.14 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 26 | $201.15 |
| 84100 | <1% | 54 | $176.79 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 28 | $168.07 |
| 86850 | <1% | 41 | $153.56 | |
| 86900 | <1% | 53 | $126.43 | |
| J2704 | Injection, propofol, 10 mg | <1% | 13 | $99.92 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 16 | $98.09 |
| 97161 | <1% | 12 | $97.20 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 200 | $96.10 |
| 90839 | <1% | 13 | $95.51 | |
| Q3014 | Telehealth originating site facility fee | <1% | 17 | $68.35 |
| 96376 | <1% | 25 | $67.20 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 14 | $59.28 |
| 87147 | <1% | 12 | $46.17 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 604 | $43.36 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 76 | $8.41 |
| 82947 | <1% | 15 | $4.28 | |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | 0% | 992 | $0.00 |
| 0258 | 0% | 29 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 12 | $0.00 |
| 0370 | 0% | 19 | $0.00 | |
| 82570 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.